Filing Signals

Source: SEC EDGAR Compiled 2026-11-13 17:17 UTC 23 automated checks passing

← All events

Shuttle Pharmaceuticals Holdings, Inc.

CIK 1757499 SHPH·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Finance chief departure 8-K
  2. Late filing NT 10-Q +217d
  3. Auditor change 8-K +66d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Auditor change high SEC item code

Shuttle Pharmaceuticals Holdings, Inc. moved from Forvis to Bush & Associates CPA LLC

The company dismissed the auditor. Forvis → Bush & Associates CPA LLC to a smaller firm

Evidence
Direction
dismissed
Direction label
The company dismissed the auditor
Item code
4.01
Item title
Changes in Registrant's Certifying Accountant
Predecessor auditor
Forvis
Predecessor tier
national
Severity
high
Source
SEC 8-K item code
Successor auditor
Bush & Associates CPA LLC
Successor tier
other
Tier downgrade
Yes
Why
The company's independent registered accounting firm changed.

Source filing ↗

Auditor change SEC item code

Shuttle Pharmaceuticals Holdings, Inc. reported a change in its independent accounting firm

The company dismissed the auditor. Forvis → not stated No disagreements disclosed.

Evidence
Direction
dismissed
Direction label
The company dismissed the auditor
Disagreements disclosed
No
Item code
4.01
Item title
Changes in Registrant's Certifying Accountant
Predecessor auditor
Forvis
Predecessor tier
national
Severity
normal
Source
SEC 8-K item code
Why
The company's independent registered accounting firm changed.

Source filing ↗

Late filing elevated Filing comparison

Shuttle Pharmaceuticals Holdings, Inc. filed its quarterly report late and said it expects a significant change in results

expects significant change in results 3 days past the statutory due date.

The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the disclosures required to be included in its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 (the “Quarterly Report”). The Registrant expects to file the Quarterly Report no later than the fifth calendar day following the prescribed filing date. SEC 1344 (04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Evidence
Anticipates significant change
Yes
Days past due date
3
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the disclosures required to be included in its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 (the “Quarterly Report”). The Registrant expects to file the Quarterly Report no later than the fifth calendar day following the prescribed filing date. SEC 1344 (04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Finance chief departure elevated Filing comparison

Shuttle Pharmaceuticals Holdings, Inc.'s Chief Financial Officer departed, replaced on an interim basis

Evidence
Interim only
Yes
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
elevated
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗